Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 1/2008

01-01-2008

Aberrant Expression of Soluble Co-stimulatory Molecules and Adhesion Molecules in Type 2 Diabetic Patients with Nephropathy

Authors: C. K. Wong, Amy W. Y. Ho, Peter C. Y. Tong, C. Y. Yeung, Juliana C. N. Chan, Alice P. S. Kong, Christopher W. K. Lam

Published in: Journal of Clinical Immunology | Issue 1/2008

Login to get access

Abstract

Co-stimulatory molecules together with leukocyte adhesion molecules are important for T lymphocyte and leukocyte-mediated inflammatory responses. We investigated the soluble costimulatory molecules CD80, CD86, CD28, and CTLA-4 and soluble adhesion molecules in plasma of 94 type 2 diabetic patients with or without nephropathy (DN and NDN) and 20 healthy controls. Plasma concentration of sCTLA-4 was significantly lower, whereas sCD28 was significantly higher in DN patients than that in control subjects (all P < 0.05). sCD28 and sCD80 were found to be positively correlated with fasting urine albumin: creatinine ratio in DN patients but not in NDN patients. Elevated soluble adhesion molecule vascular cell adhesion molecule-1 and P-selectin could be related with the disease severity of DN (all P < 0.05). Therefore, the aberrant expression of soluble co-stimulatory molecules and adhesion molecules can be related to the activation of T cells and leukocytes in the progression of inflammation in diabetic nephropathy.
Literature
1.
Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–23.PubMedCrossRef
2.
Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein- kinase. Diabetologia. 2004;47:532–6.PubMedCrossRef
3.
Wong CK, Ho AWY, Tong PCY, et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with diabetic nephropathy. Clin Exp Immunol. 2007;149:123–31.PubMedCrossRef
4.
5.
Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol. 1998;18:389–418.PubMed
6.
Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA. 1990;87:5031–5.PubMedCrossRef
7.
Sfikakis PP, Via CS. Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy. Clin Immunol Immunopathol. 1997;83:195–8.PubMedCrossRef
8.
Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225–52.PubMedCrossRef
9.
Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561–9.PubMedCrossRef
10.
Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233–58.PubMedCrossRef
11.
Wong CK, Lun SWM, Ko FWS, Ip WK, Hui DSC, Lam CWK. Increased expression of plasma and cell surface costimulatory molecules CTLA-4, CD28 and CD86 in adultpatients with allergic asthma. Clin Exp Immunol. 2005;141:122–9.PubMedCrossRef
12.
Wong CK, Lit LCW, Li EKM, Tam LS, Lam CWK. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology. 2005;44:989–94.PubMedCrossRef
13.
Chiappara G, Gagliardo R, Siena A, et al. Airway remodelling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol. 2001;1:85–93.PubMed
14.
Radi ZA, Kehrli ME Jr, Ackermann MR. Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J Vet Intern Med. 2001;15:516–29.PubMedCrossRef
15.
16.
Wong CK, Wang CB, Li MLY, Ip WK, Tian YP, Lam CWK. Induction of adhesion molecules upon the interaction between eosinophils and epithelial cells: Involvement of p38 MAPK and NF-κB. Int Immunopharmacology. 2006;6:1859–71.CrossRef
17.
Jarvisalo MJ, Juonala M, Raitakari OT. Assessment of inflammatory markers and endothelial function. Curr Opin Clin Nutr Metab Care. 2006;9:547–52.PubMedCrossRef
18.
World Health Organization Technical report series 727. Diabetes Mellitus. Geneva: WHO; 1985.
19.
Viallard JF, Pellegrin JL, Ranchin V. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999;115:189–95.PubMedCrossRef
20.
Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28:659–82.PubMedCrossRef
21.
Wong CK, Szeto CC, Chan MHM, Leung CB, Li PKT, Lam CWK. Elevation of pro-inflammatory cytokines, C-reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. Immunol Invest. 2007;36:47–57.PubMedCrossRef
22.
Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol. 2000;201:144–53.PubMedCrossRef
23.
Magistrelli G, Jeannin P, Elson G. Identification of three alternatively spliced variants of human CD28 mRNA. Biochem Biophys Res Commun. 1999;259:34–7.PubMedCrossRef
24.
Hebbar M, Jeannin P, Magistrelli G, et al. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin Exp Immunol. 2004;136:388–92.PubMedCrossRef
25.
Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol. 2004;5:1134–42.PubMedCrossRef
26.
del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol. 1999;276:E849–55.PubMed
27.
Park CW, Kim JH, Lee JH, et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia. 2000;43:1544–53.PubMedCrossRef
28.
Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol. 2005;16:1711–22.PubMedCrossRef
29.
Guler S, Cakir B, Demirbas B, et al. Plasma soluble intercellular adhesion molecule 1 levels are increased in type 2 diabetic patients with nephropathy. Horm Res. 2002;58:67–70.PubMedCrossRef
30.
Knudsen H, Andersen CB, Ladefoged SD. Expression of the intercellular adhesion molecule-3 (ICAM-3) in human renal tissue with relation to kidney transplants and various inflammatory diseases. APMIS. 1995;103:593–6.PubMedCrossRef
31.
Berney SM, Schaan T, Alexander JS, et al. ICAM-3 (CD50) cross-linking augments signaling in CD3-activated peripheral human T lymphocytes. J Leukoc Biol. 1999;65:867–74.PubMed
32.
Montoya MC, Sancho D, Bonello G, et al. Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. Nat Immunol. 2002;3:159–68.PubMedCrossRef
33.
Murakami H, Tamasawa N, Matsui J, Yamato K, JingZhi G, Suda T. Plasma levels of soluble vascular adhesion molecule-1 and cholesterol oxidation product in type 2 diabetic patients with nephropathy. J Atheroscler Thromb. 2001;8:21–4.PubMed
34.
35.
Figarella-Branger D, Schleinitz N, Boutiere-Albanese B, et al. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies. J Rheumatol. 2006;33:1623–30.PubMed
36.
37.
Hirata K, Shikata K, Matsuda M. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia. 1998;41:185–92.PubMedCrossRef
38.
Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000;97:13835–40.PubMedCrossRef
Metadata
Title
Aberrant Expression of Soluble Co-stimulatory Molecules and Adhesion Molecules in Type 2 Diabetic Patients with Nephropathy
Authors
C. K. Wong
Amy W. Y. Ho
Peter C. Y. Tong
C. Y. Yeung
Juliana C. N. Chan
Alice P. S. Kong
Christopher W. K. Lam
Publication date
01-01-2008
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 1/2008
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-007-9137-4

Other articles of this Issue 1/2008

Journal of Clinical Immunology 1/2008 Go to the issue

OriginalPaper

Pentraxins in Innate Immunity: From C-Reactive Protein to the Long Pentraxin PTX3

OriginalPaper

Increased Serum Levels of Soluble CD30 in Patients with Common Variable Immunodeficiency and Its Clinical Implications

OriginalPaper

The Expression of Retinoic Acid Receptors in Thymus of Young Children and the Effect of All-Transretinoic Acid on the Development of T Cells in Thymus

Erratum

Analyses of CD27++ Plasma Cells in Peripheral Blood from Patients with Bacterial Infections and Patients with Serum Antinuclear Antibodies

Erratum

Effects of Tumour Necrosis Factor-α on Human Sperm Motility and Apoptosis

OriginalPaper

The Influence of Polymorphisms of Interleukin-17A and Interleukin-17F Genes on the Susceptibility to Ulcerative Colitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits